Updates are available Correction dated 2023-07-06
Click to view Correction: https://doi.org/10.1038/s41408-023-00866-y
-
Authors
Raje, Noopur https://orcid.org/0000-0003-3066-1275
Mateos, María-Victoria https://orcid.org/0000-0003-2390-1218
Iida, Shinsuke
Reece, Donna
- License Information
-
More Information
Article History
Received: 9 August 2022
Revised: 7 February 2023
Accepted: 23 February 2023
First Online: 22 March 2023
Change Date: 6 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-023-00866-y
Competing interests
: NR reports consulting for Amgen, Bristol Myers Squibb, Janssen, Sanofi, Takeda, AstraZeneca, and C4 Therapeutics, and serving on the advisory boards of Caribou and Immuneel, and research funding from bluebird bio; M-VM reports payment or honoraria from Janssen, Bristol Myers Squibb, Amgen, Takeda, GlaxoSmithKline, Sanofi, Regeneron, Pfizer, and Seagen; SL reports receiving support for the present manuscript from Bristol Myers Squibb, and grant or contract support from Bristol Myers Squibb, Janssen, Sanofi, Pfizer, AbbVie, Daiichi Sankyo, Takeda, Ono, Chugai, Amgen, GlaxoSmithKline, and Kyowa Kirin, and payments or honoraria from Bristol Myers Squibb, Janssen, Takeda, Ono, Pfizer, Sanofi, and Celgene; DR reports consulting fees from Janssen, Bristol Myers Squibb, Amgen, and Takeda, and payment or honoraria from Janssen, Bristol Myers Squibb, Amgen, Takeda, and Merck, and research funding from Janssen, Bristol Myers Squibb, Amgen, Otsuka, Merck, and Takeda, and serving on the board of directors or advisory committees for Janssen and Bristol Myers Squibb.
